We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Merck and Co Inc | NYSE:MRK | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.43 | 0.33% | 131.15 | 131.91 | 130.13 | 130.13 | 7,757,432 | 01:00:00 |
From Apr 2019 to Apr 2024
By Colin Kellaher
Merck & Co. on Monday said the U.S. Food and Drug Administration accepted for review its new-drug application for gefapixant for the treatment of refractory chronic cough or unexplained chronic cough in adults.
The Kenilworth, N.J., drugmaker said the FDA set a target action date of Dec. 21 for the review, adding that the agency plans to discuss the application at an advisory committee meeting, which has yet to be scheduled.
Merck said there are currently no approved therapies for the treatment of refractory or unexplained chronic cough.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
March 01, 2021 07:33 ET (12:33 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Merck Chart |
1 Month Merck Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
